|کد مقاله||کد نشریه||سال انتشار||مقاله انگلیسی||ترجمه فارسی||نسخه تمام متن|
|6000422||1579200||2016||3 صفحه PDF||سفارش دهید||دانلود کنید|
- The relation of gamma prime (Î³â²) fibrinogen with cardiovascular disease (CVD) remains equivocal.
- Prospective associations of Î³â² fibrinogen with CVD are limited.
- We failed to show associations between Î³â² fibrinogen and CVD endpoints beyond CVD risk factors.
IntroductionThe association of gamma prime (Î³â²) fibrinogen; a fibrinogen Î³ chain variant generated via alternative mRNA processing, with cardiovascular disease (CVD) remains equivocal. We prospectively examine the association of plasma Î³â² fibrinogen with the incidence of multiple cardiovascular disease (CVD) endpoints, independent of established CVD risk factors and total fibrinogen.Materials and methodsWe measured plasma Î³â² fibrinogen on plasma samples collected in 1992-1993 from adults â¥Â 65Â years (nÂ =Â 3219) enrolled in the Cardiovascular Health Study, who were followed through 2013 for incident CVD events.Results and conclusionsIn multivariable Cox models adjusted for traditional CVD risk factors and total fibrinogen, the hazard ratio per 1 standard deviation (10.7Â mg/dl) increment of Î³â² fibrinogen was 1.02 (95%CI: 0.95-1.10) for coronary heart disease; 0.88 (0.77-1.00) for ischemic stroke; 1.07 (0.87-1.32) for peripheral artery disease; 1.00 (0.92-1.08) for heart failure and 1.01 (0.92-1.10) for CVD mortality. Likewise, we failed to show a statistically significant association of Î³â²/total fibrinogen ratio with any CVD endpoint. These results suggest that among the elderly, Î³â² fibrinogen does not add much to CVD prediction beyond traditional risk factors and total fibrinogen level.
Journal: Thrombosis Research - Volume 143, July 2016, Pages 50-52